The emergence of H7N9 viruses: A chance to redefine correlates of protection for influenza virus vaccines

Expert Review of Vaccines

Volumn 12, Issue 12, 2013, Pages 1369-1372

  Krammer, Florian ^a   Cox, Rebecca J ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

correlates of protection; H7N9; hemagglutinin; immunity; influenza virus; pandemic; stalk reactive antibodies

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

CD4+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNITY; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA VIRUS A; INFLUENZA VIRUS A H7N9; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTIGENS, VIRAL; BIOLOGICAL MARKERS; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84887694501     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.850036     Document Type: Review

References (27)

1. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70(4), 767-777 (1972).
2. Couch RB, Decker WK, Utama B et al. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS ONE 7(12), e50830 (2012).
3. Cox RJ, Madhun AS, Hauge S et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27(13), 1889-1897 (2009).
4. Gao R, Cao B, Hu Y et al. Human infection with a novel avian-origin influenza a (H7N9) virus. N. Engl. J. Med. 368(20), 1888-1897 (2013).
5. Xiong X, Martin SR, Haire LF et al. Receptor binding by an H7N9 influenza virus from humans. Nature 499(7459), 496-499 (2013).
6. Watanabe T, Kiso M, Fukuyama S et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501(7468), 551-555 (2013).
7. Ramos I, Krammer F, Hai R et al. H7N9 influenza viruses interact preferentially with a2,3-linked sialic acids and bind weakly to a2,6-linked sialic acids. J. Gen. Virol. doi:10.1099/vir.0.056184-0 (2013) (Epub ahead of print).
8. Hu Y, Lu S, Song Z et al. Association between adverse clinical outcome in human disease caused by novel influenza a H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381(9885), 2273-2279 (2013).
9. Cox RJ, Major D, Hauge S et al. A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respi. Viruses 3(3), 107-117 (2009).
10. Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr. Opin. Virol. 2(2), 134-141 (2012).
11. Pica N, Hai R, Krammer F et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl Acad. Sci. USA 109(7), 2573-2578 (2012).
12. Krammer F, Pica N, Hai R, Margine I, Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87(12), 6542-6550 (2013).
13. Margine I, Hai R, Albrecht RA et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J. Virol. 87(8), 4728-4737 (2013).
14. Wei CJ, Yassine HM, McTamney PM et al. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci. Transl. Med. 4(147), 147ra114 (2012).
15. Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. doi:10.1016/j. coviro.2013.07.007 (2013) (Epub ahead of print).
16. Margine I, Krammer F, Hai R et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza a viruses. J. Virol. doi:10.1128/JVI.01715-13 (2013) (Epub ahead of print).
17. Palese P, Wang TT. Why do influenza virus subtypes die out? A hypothesis. MBio 2(5) (2011).
18. Easterbrook JD, Schwartzman LM, Gao J et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432(1), 39-44 (2012).
19. Wan H, Gao J, Xu K et al. Molecular Basis for Broad Neuraminidase Immunity: Conserved Epitopes in Seasonal and Pandemic H1N1 as Well as H5N1 Influenza Viruses. J. Virol. 87(16), 9290-9300 (2013).
20. Rockman S, Brown LE, Barr IG et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J. Virol. 87(6), 3053-3061 (2013).
21. Talaat KR, Karron RA, Callahan KA et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 27(28), 3744-3753 (2009).
22. el-Madhun AS, Cox RJ, Soreide A, Olofsson J, Haaheim LR. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J. Infect. Dis. 178(4), 933-939 (1998).
23. Wilkinson TM, Li CK, Chui CS et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18(2), 274-280 (2012).
24. Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877-3882 (2009).
25. Pedersen GK, Madhun AS, Breakwell L et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J. Infect. Dis. 206(2), 158-166 (2012).
26. Pathirana RD, Bredholt G, Akselsen PE, Pedersen GK, Cox RJ. A(H1N1) pdm09 vaccination of healthcare workers: improved immune responses in low responders following revaccination. J. Infect. Dis. 206(11), 1660-1669 (2012).
27. McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176(10), 6333-6339 (2006).